Predicting recurrence in CRC using post-operative circulating tumour DNA
September 2023 Circulating tumour DNA (ctDNA) refers to the fragments of genetic material (DNA) from tumours that can be detected in the blood. A ctDNA negative result means that no remaining cancer was detected by the test. While this does not guarantee that the cancer will not come back, studies show that patients who a...
CONTINUE READING
Exercise linked to lower mortality risk across different cancer types
September 2023 After a cancer diagnosis, the impact of exercise on cancer and non-cancer mortality among survivors, and whether the benefit of exercise differs depending on the cancer type, remains unclear. A recent study found that regular exercise can significantly reduce a cancer survivor’s risk of dying from cancer an...
CONTINUE READING
Coping with Metastatic Cancer
Learning that you have metastatic cancer can be a physically and emotionally life-changing moment. Many emotions may arise, including uncertainty, anger, confusion, sadness, fear, and many others. The plans you once had may be up in the air, and you may not be sure what will happen next. You may be angry or confused because ...
CONTINUE READING
The FDA approves Lonsurf plus bevacizumab for metastatic colorectal cancer
August 2023 The US Food and Drug Administration (FDA) has approved the combination therapy of trifluridine/tipiracil (Lonsurf) and bevacizumab for the treatment of adults with metastatic colorectal cancer (mCRC) who have received previous treatment with 5-FU-, oxaliplatin- and irinotecan-based chemotherapy (such as FOLFOX...
CONTINUE READING
Liver transplant improves survival for certain patients with colorectal cancer liver metastases
August 2023 A recent study demonstrated that a liver transplant provided a 10-year overall survival (OS) rate of more than 80% for selected patients with colorectal cancer (CRC) and nonresectable liver metastases. Non-resectable liver metastases: liver metastases that cannot be safely removed with surgery, for reasons ...
CONTINUE READING
